

February 7, 2017

BSE Limited Floor 25, P. J. Towers Dalal Street, Mumbai - 400 001 The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Dear Sirs,

Re.: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Acquisition of Preference Shares in subsidiary company

The Board of Directors of the Company has, at its meeting held today, approved acquisition of 18,66,20,000 12% Optionally Convertible Non-cumulative Redeemable Preference Shares of Rs. 10 each of Jubilant Biosys Limited at par aggregating to Rs. 186.62 crore, subject to applicable laws. Details pursuant to Regulation 30 are given in **Annexure-A**.

We request you to take the same on record.

Thanking you,

Yours faithfully, For Jubilant Life Sciences Limited

Rajiv Shah Company Secretary

Encl.: As above

A Jubilant Bhartia Company



Regd Office: Bhartiagram, Gajraula Distt. Amroha - 244 223, UP, India CIN: L24116UP1978PLC004624



Annexure-A

Details of Acquisition of Preference Shares

Sr. No.	Particulars	Details		
1.	Name of the target entity, details in brief such as size, turnover etc.	 Jubilant Biosys Limited (* <u>FY 2015-16</u> <u>Turnover</u>: Rs 5,884.70 <u>EBITDA</u>: Rs (455.81) Lac	
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	The proposed acquisition Optionally Convertible Redeemable Preference Shares') is a Related Par is being executed on arm' The promoters of the Con Bhartia and Mr. Hari S. the companies controlled equity shares of Bio particulars: Sr. Name of No. Shareholder 1 Mr. Shyam S. Bhartia 2 Mr. Hari S. Bhartia 3 Jubilant Capital Private Limited 4 Jubilant Enpro Private Limited 5 Jubilant Stock Holding Private Limited Total	le Non-c Shares ('I ty Transaction is length basin mpany, Mr. Bhartia, togo I by them, I sys as pe	on, which s. Shyam S. ether with hold 33%
3.	Industry to which the entity being acquired belongs	The proposed transaction involves acquisition of Preference Shares of Biosys. Hence, no entity shall be acquired through this transaction.		





	· · · · · · · · · · · · · · · · · · ·		
		Biosys is engaged in providing drug discovery and development and other related services to support the pharmaceutical/ biotechnology industry.	
4,	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Rs. 186.62 crore. The loans granted earlier shall	
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable	
6.	Indicative time period for completion of the acquisition	Approximately 3 months	
7,,	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration	
8.	Cost of acquisition or the price at which the shares are acquired	At par i.e. Rs. 10 per Preference Share	
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	18,66,20,000 Preference Shares of Rs. 10 each at par aggregating to Rs. 186.62 Crore i.e. 100% holding of Preference Shares. No control shall be acquired as the proposed subscription is for Preference Shares.	
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	As stated above, the proposed subscription of Preference Shares shall not result in acquisition of Biosys. The relevant details of Biosys are given below: Products/line of business: Scientific and Technical consultancy services Date of incorporation: 10.02.1998	
		E SCIEN	





Turnover of last three years:

2013-14: Rs 9,798.02 Lac 2014-15: Rs 5,824.32 Lac 2015-16: Rs 5,884.70 Lac

Country in which Biosys has presence:

a. India

b. US (through 100% Subsidiary Company- Jubilant Discovery Services Inc)

